South San Francisco, CA October 26, 2017 Genentech Press Release New OCREVUS (Ocrelizumab) Data at ECTRIMS Advance Clinical Understanding of Underlying Progression in Multiple Sclerosis Data show superiority of OCREVUS compared to Rebif (interferon beta-1a) in significantly reducing disability Progression…
Tag: Genentech
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
South San Francisco, CA September 10, 2017 Genentech Press Release Spectri study did not meet its primary endpoint of reducing mean change in geographic atrophy lesion area in patients treated with lampalizumab compared with sham treatment Safety profile was…
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
South San Francisco, CA August 28, 2017 Genentech Press Release SOUTH SAN FRANCISCO, CA — 2017-08-27 00:00:00 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has…
FDA Grants Priority Review to Genentech’s Emicizumab for Hemophilia A with Inhibitors
South San Francisco, CA August 24, 2017 Genentech Press Release Application based on positive results of Phase III study in adults and adolescents with hemophilia A with inhibitors and interim Phase III results in children — SOUTH SAN FRANCISCO,…
FDA Grants Genentech’s Alecensa Priority Review for Initial Treatment of People with ALK-Positive Lung Cancer
South San Francisco, CA August 2, 2017 Genentech Press Release Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New…
SSFUSD Teacher Michael Tom Recognized by Genentech – Rebroadcast
South San Francisco, CA July 31, 2017 by Genentech – Rebroadcast THIS IS A REBROADCAST FROM GENENTECH AS SHARED ON THEIR SOCIAL MEDIA AND THEIR WEBSITE Growing up in the city of South San Francisco, Michael Tom…
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
South San Francisco, CA July 10, 2017 Genentech Press Release Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine HAVEN 1 showed emicizumab reduced bleed rate by 87 percent…
Genentech’s Emicizumab Showed Positive Results in Phase III Studies (HAVEN 1 And HAVEN 2) in Hemophilia A With Inhibitors
South San Francisco, CA June 27, 2017 Press Release Genentech — Emicizumab showed substantial and clinically meaningful reduction in bleeds across two pivotal studies — — Data from HAVEN 1 in adults and adolescents and interim data from HAVEN…
New Data at EAN Show Genentech’s Ocrevus (Ocrelizumab) Significantly Reduced Multiple Measures of Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis
South San Francisco, CA June 23, 2017 Genentech Press Release OCREVUS increased the number of patients with relapsing MS (RMS) and primary progressive MS (PPMS) who maintained No Evidence of Progression or Active Disease (NEPAD) versus Rebif® (interferon beta-1a)…
FDA Approves Rituxan Hycela (Rituximab and Hyaluronidase Human) for Subcutaneous Injection in Certain Blood Cancers
South San Francisco, CA June 23, 2017 Genentech Press Release Treatment can be administered in five to seven minutes, compared to 1.5 hours or more for intravenous Rituxan — SOUTH SAN FRANCISCO, CA — 2017-06-22 00:00:00 Genentech, a member…